In this episode, we explore a challenge facing many science-led startups: the transition from a founder-carried narrative to a market-carried narrative. Using ProTGen as a case study, we unpack why the next stage of growth requires more than a polished pitch deck, refreshed website, or redesigned one-pager. It requires what we call portable conviction. 

We discuss:

• Why great science often suffers from having too many compelling stories
• The difference between explaining a company and creating belief in a company
• How investors, partners, and stakeholders process complex scientific narratives
• The critical role of narrative sequencing: problem → solution → proof → platform
• Why ProT-096 should serve as a bridge between today's clinical reality and tomorrow's platform opportunity
• How manufacturing, partnerships, and operational milestones become credibility-building proof points
• The concept of a "story spine" and why every communication asset should flow from it
• Practical ways to test whether your story is clear, memorable, and retellable

Along the way, we examine a fundamental strategic question: What should your audience believe first?

Whether you're a biotech founder, investor, innovation leader, or strategist working with complex technologies, this conversation offers a framework for transforming scientific complexity into market conviction.

Because the ultimate goal isn't creating better materials.

It's building a story that can walk into the room on its own.